Moreover, a phase II trial (NCT02091960) that combined enzalutamide with the anti-HER2 antibody trastuzumab, in advanced AR+/HER2+/ER− BC groups, indicated that about a quarter of the participants exhibit partial response or stable disease during the 24-week treatment period [272]. The gene discussed is ERBB2; the disease is breast cancer.